APC-Labeled Monoclonal Anti-G4S linker Antibody, Rabbit IgG (016), premium grade

Catalog # G4S-HFM25G0



Source

APC-Labeled Monoclonal Anti-G4S linker Antibody, Rabbit IgG (016), premium grade is a rabbit monoclonal antibody recombinantly expressed from human 293 cells (HEK293), which provides higher batch consistency and long term security of supply. It shows superior performance in flow cytometry assays with higher affinity and better specificity.

It is produced under our rigorous quality control system that incorporates a comprehensive set of tests including sterility and endotoxin tests. Product performance is carefully validated and tested for compatibility for cell culture use or any other applications in the early preclinical stage. When ready to transition into later clinical phases, we also offer a custom GMP protein service that tailors to your needs. We will work with you to customize and develop a GMP-grade product in accordance with your requests that also meets the requirements for raw and ancillary materials use in cell manufacturing of cell-based therapies.

Isotype

Rabbit IgG | Rabbit Kappa

Conjugate

APC

Excitation Wavelength: 640 nm

Emission Wavelength: 661 nm

Application

Flow Cytometry (Evaluation of cell surface expressed CARs of varying specificity containing a G4S linker within the scFv of the extracellular domain).

Specificity

Specifically recognizes the scFv-based CARs containing a G4S linker.

Endotoxin

Less than 0.1 EU per test by the LAL method.

Sterility

Negative

Mycoplasma

Negative.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, 0.2% rHSA, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

This product is stable after storage at:

- -20°C to -70°C for 24 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution;
- 2-8°C for 12 months under sterile conditions after reconstitution.


Bioactivity-FACS




APC-Labeled Monoclonal Anti-G4S linker Antibody, Rabbit IgG (016), premium grade


Catalog # G4S-HFM25G0





Flow cytometric analysis of Anti-MSLN CAR-293 cells staining with APC-Labeled Monoclonal Anti-G4S linker Antibody, Rabbit IgG (016), premium grade (Cat. No. G4S-HFM25G0) at 1:50 dilution (2 μ L of the antibody stock solution corresponds to labeling of 1e6 cells in a final volume of 100 μ L), compared with isotype control antibody. APC signal was used to evaluate the binding activity (QC tested).





Non-specificity of APC-Labeled Monoclonal Anti-G4S linker Antibody, Rabbit IgG (016), premium grade (Cat. No. G4S-HFM25G0) binding to CD3+cells present in human PBMC. 5e5 of human PBMCs were simultaneously stained with FITC-labeled anti-CD3 antibody and APC-Labeled Anti-G4S linker Antibody (016) (2 μ L of the antibody stock solution corresponds to labeling of 5e5 cells in a final volume of 100 μ L) and washed and then analyzed with FACS. Both FITC and APC positive signals was used to evaluate the non-specific binding activity to human CD3+ cells (QC tested).

Background

The poly-Glycine-Serine (G4S) linker is a type of flexible, unstructured synthetic peptide linker sequence often leveraged to connect the variable heavy (VH) domain and variable light (VL) domain of single-chain variable fragments (scFvs) and chimeric antigen receptors (CARs) that utilize an extracellular domain scFv for target antigen recognition. The linker itself consists of a core pentapeptide sequence, Gly-Gly-Gly-Gly-Ser, that is repeated and commonly found as either a 15-mer (G4S)3 or20-mer(G4S) 4 within scFv-based CARs and scFv fragments. The linker sequence length plays a role in controlling scFv stability and the noncovalent association between the VH and VL domains.

Clinical and Translational Updates

